Detection of ESBL, AmpC, and MBL-Producing Chryseobacterium indologenes Isolates Recovered from Hospital Environment in a Tertiary Health Care Facility

Ezeador Chika Ogochukwu^1, , Agbakoba Nneka Regina¹, Ushie Simon Nkpeh¹, Akuakolam Ikenna Macmagnus¹, Elemuo Grace¹, Ugochukwu Ikenna² and Ejikeugwu Chika Peter³

¹Department of Medical Microbiology & Parasitology, Faculty of Medicine, Nnamdi Azikiwe University, Awka, Nigeria

²Department of Health Services, Alvan Ikoku Federal College of Education, Orlu Road, P.M.B 1033 Owerri, Nigeria

³Department of Applied Microbiology, Faculty of Science, Ebonyi State University, P.M.B. 053, Abakaliki, Nigeria

Cite this paper:
Ezeador Chika Ogochukwu, Agbakoba Nneka Regina, Ushie Simon Nkpeh, Akuakolam Ikenna Macmagnus, Elemuo Grace, Ugochukwu Ikenna and Ejikeugwu Chika Peter. Detection of ESBL, AmpC, and MBL-Producing Chryseobacterium indologenes Isolates Recovered from Hospital Environment in a Tertiary Health Care Facility. American Journal of Infectious Diseases and Microbiology. 2021; 9(4):129-135. doi: 10.12691/ajidm-9-4-4

Abstract

Objective: Chryseobacterium indologenes are aerobic, Gram negative, non-fermentative rods that are intrinsically multidrug-resistant. Although an uncommon environmental pathogen, C. indologenes has been implicated recently in nosocomial infections and very resistant to plethora of antibiotics. The aim of this study is to phenotypically determine the occurrence of extended spectrum beta-lactamase (ESBL), cephalosporinase (AmpC) and metallo-beta-lactamase (MBL) production in isolates of Chryseobacterium indologenes recovered from hospital environment. Material and Methods: Hundred and eight (104) environmental samples were collected from different inanimate sources from hospital wards out of which fourteen (14) of them were from the floors and sixteen (16) of them from sinks. The isolates were identified and characterized using a commercial test kit, API 20NE^® BioMérieux, France following preliminary isolation and identification on three culture media. The identified bacteria subsequently were subjected to Antimicrobial Susceptibility Testing using Kirby Bauer agar disk diffusion method according to CLSI standard. Extended spectrum β-lactamase production was determined phenotypically by Double Disc Synergy Test (DDST) using Ceftazidime and Cefotaxime alone and in combination with Clavulanic acid. AmpC production was also determined using Cefoxitin and Ceftazidime – Double Disk Synergy Test (CC-DDST) and Ceftazidime-Imipenem antagonistic test (CIAT) methods so as to detect both inducible and constitutive AmpC production, whereas MBL detection was done by Imipenem EDTA Combined Disc Diffusion Test and using Modified Hodges Test (MHT). Results: Of the twenty isolates recovered, two (47.8%) of the bacteria isolated were C. indologenes. The two non-duplicate isolates were recovered from the floor and a sink in Paediatrics Ward and Male Surgical Ward respectively. On Mueller Hinton Agar (MHA), the bacteria produced a characteristic yellowish pigmentation. Antimicrobial susceptibility testing (AST) revealed both bacteria as multidrug-resistant to different classes of antimicrobials used against them. The organisms were resistant to Amoxiclav (100%), third generation-cephalosporins (3GC) (100%), monobactam (100%), carbapenems (100%), aminoglycosides (100%), lipopeptides (100%), and glyclycycline (100%) used. However, they were completely susceptible to piperacillin, piperacillin-tazobactam and ciprofloxacin (100%). The isolates also showed a multiple resistance index of 0.8. C. indologenes isolates recovered from hospital environment were found to phenotypically produce β-lactamases including ESBL, AmpC and MBL. Conclusion: The isolation of C. indologenes from hospital environment in this study should be a concern to us as its route into humans may be very lethal considering its multidrug-resistant nature. This study therefore encourages proper infection control measures to be advocated in health facilities, need to maintain good hygiene in hospital environment, as well as regular handwashing so as to minimize or prevent the cross transmission of this pathogen to patients as the resultant effect may be unprecedented. There may also be need for Clinical Microbiologists, Laboratory Scientists and Pathologist to routinely include the isolation and identification of these less reported non-fermenting Gram-negative bacteria in their laboratories.

Keywords:
Extended Spectrum-β-lactamase Metallo-β-lactamase AmpC-β-lactamase Chryseobacterium indologenes non-fermenting bacteria

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Lin, Y., Jeng, Y., Lin, M., Yu, K., Wang, F. and Liu, C., “Clinical and Microbiological Characteristics of Chryseobacterium indologenes Bacteremia,” J Microbiol Immunol Infect, 43(6). 498-505. 2010.
[2]	Hsueh, P., Hsiue, T. and Wu, J, “Flavobacterium indologenes Bacteremia: Clinical and Microbiological Characteristics,” Clin Infect Dis, 23(138). 550-555, Sep. 1996.
[3]	Andy, I.E. and Okpo, E.A, “Prevalence of Potential Nosocomial Bacterial Pathogens in Liquid Waste and Waste Dump Soil of Three Major Hospitals in Calabar Metropolis, South-South Nigeria,” World J Pharm Res.: 7(17). 134-147, 2018.
[4]	Robinson, V.K. and Wemedo, S.A, “Molecular Characterization of Indoor air Microorganisms of a Model Primary Health Care in Port Harcourt, Rivers State, Nigeria,” Asian J Biotechnol Genet Eng. 2(1). 1-9. Mar. 2019.
[5]	Steinberg, J.P. and Burd, E.M, Other Gram-Negative and Gram-Variable Bacilli. In: Mandell GL, Bennett JE, Dolin R, editors. Principles And Practice of Infectious Diseases. 7th ed. Philadelphia, PA 19103: Churchhill Livingstone Elsevier; 2010. p. 3022-3.
[6]	Andy, I.E. and Okpo, E.A, “Plasmid Profile Analysis and Curing of Multidrug Resistant Bacteria Isolated from Hospital Waste Dump Site in Calabar Metropolis, Nigeria,” Eur J Pharm Med Res, 6(5). 54-61. Apr.2019.
[7]	Mehta, R. and Pathak, A, “Emerging Chryseobacterium indologenes Infection in Indian Neonatal Intensive Care Units : A Case Report,” Antibiotics, 7(109). 1-5. Dec.2018
[8]	Cimmino, T. and Rolain, J, “Whole genome sequencing for deciphering the resistome of Chryseobacterium indologenes, an emerging multidrug-resistant bacterium isolated from a cystic fi brosis patient in Marseille , France,” New Microbes New Infect, 12: 35-42. Mar.2016.
[9]	Mukerji, R., Kakarala, R., Smith, S.J. and Kusz, H.G, “Chryseobacterium indologenes: an emerging infection in the USA,” BMJ Case Rep, Apr.2016.
[10]	Alfouzan, W., Dhar, R., Al-hashemi, H., Al-sweih, N. and Albert, M.J, “Clinical and microbiological characteristics of Chryseobacterium spp. isolated from neonates in Kuwait Case Report,” J Med Case Rep, 1-6. Jul.2014.
[11]	Izaguirre-anariba, D.E. and Sivapalan, V, “Chryseobacterium indologenes, an Emerging Bacteria: A Case Report and Review of Literature,” Cureus, 12(1). 1-7. Jan.2020.
[12]	Chang, Y., Lo, H. and Hsieh, H, “Identification, epidemiological relatedness, and biofilm formation of clinical Chryseobacterium indologenes isolates from central Taiwan,” J Microbiol Immunol Infect, 48(5). 559-564. Apr.2014.
[13]	Solanke, V., Verma, S., Nataraj, G. and Mehta, P, “Chryseobacterium indologenes Associated Urinary Tract Infection – A Case Report,” Br Biomed Bull, 3(1) 75-80. Feb.2015.
[14]	Ozcan, N., Dal, T., Tekin, A., Kelekci, S., Can. S., Ezin, O., Kandemir, I. and Kadri, G, “Is Chryseobacterium indologenes a Shunt-lover Bacterium? A Case Report and Review of the Literature,” Le Infez Med, 2. 312-316. 2013.
[15]	Das, P., Karade, S., Kaur, K., Ramamurthy, R. and Ranjan, P, “Chryseobacterium Indologenes Pneumonitis in an Infant: A Case Report,” Journal of Clinical and Diagnostic Research, 11(6). 10-11. Jun.2017.
[16]	Bhuyar, G., Jain, S., Shah, H. and Mehta, V.K, “Urinary tract infection by Chryseobacterium indologenes,” Indian J Med Microbiol, 30(3). 370-372. Sep.2012.
[17]	Atıcı, S., Ünkar, Z.A., Erdem, K., Kadayifci, E.K., Karaaslan, A., Memişoğlu, A.Ç., Soysal, A., Toprak, N.Ü., Söyletir, G., Özek, E. and Bakır, M, “Ventilator associated pneumonia caused by Chryseobacterium indologenes: a rare infant case and review of the literature,” Springerplus. 5. 1741-1775. Oct. 2016.
[18]	Zhang, Y., Li, D., Yang, Y., Su, J., Xu, X., Wang, M., Yijian, C. and Ying, L, “Clinical and molecular characteristics of Chryseobacterium indologenes isolates at a teaching hospital in Shanghai, China,” Ann Transl Med, 9(8). 1-10. Apr.2021.
[19]	Zeba, B., Simpore, P.J., Nacoulma, O.G. and Frere, J.M, “Identification of Metallo-β-lactamase from a Clinical Isolate at Saint Camillle Medical Center of Ouagadougou, Burkinafaso,” African J Biotechnol, 4(3). 286-288. Dec.2005.
[20]	Bhagawati, G., Bhardwaj, A., Sajikumar, R., Singh, S.P. and Prajapati, S, “Bacteremia by Chryseobacterium indologenes in a Patient with Lung Cancer: A Clinical and Microbiological Investigation,” Indian J Crit Care Med, 23(3). 157-159. Mar.2019.
[21]	Lin, X., Xu, Y., Cheng, J., Li, T. and Wang, Z, “Heterogeneity of blaIND metallo-β-lactamase-producing Chryseobacterium indologenes isolates detected in Hefei, China,” Int J Antimicrob Agents, 32(5). 398-400. Apr.2008.
[22]	Luca, F. D., Dubus, A., Delmarcelle, M., Simpore, J., Nacoulma, O.G., Rossolini, G.M., Frère, J.M. and Docquier, J.D, “IND-6 , a Highly Divergent IND-Type Metallo-β-lactamase from Chryseobacterium indologenes Strain 597 Isolated in Burkina Faso,” Antimicrob Agents Chemother, 53(10). 4320-2326. Aug.2009.
[23]	Perilli, M., Caporale, B., Celenza, G., Pellegrini, C., Docquier, J.D., Mezzatesta, M., Rossolini, G.M., Stefani, S. and Amicosante, G, “Identification and Characterization of a New Metallo-β-Lactamase, IND-5, from a Clinical Isolate of Chryseobacterium indologenes,” Antimicrob. Agents and Chemother, 51(8). 2988-2990. Apr.2007.
[24]	Kirby, J.T., Sader, H.S., Walsh, T.R. and Jones, R.N, “Antimicrobial Susceptibility and Epidemiology of a Worldwide Collection of Chryseobacterium spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001),” J. Clin. Microbiol. 42(1). 445-448. Oct.2004.
[25]	Yadav, V.S., Das, B.K., Mohapatra, S., Ahmed, M.N., Gautam, H., Kapil, A., Sood, S., Dhawan, B. and Chaudhry, R, “Clinical correlation and antimicrobial susceptibility pattern of Chryseobacterium spp: A three year prospective study,” Intractable and Rare Diseases Research, 10. 37-41. Jan.2021.
[26]	Alon, D., Karniel, E., Zohar, I., Stein, G.Y., Medicine, A. and Saba, K, “Chryseobacterium indologenes Bacteremia: Clinical and Microbiological Characteristics of an Emerging Infection,” International Journal of Clinical Medicine, 9. 520-527. Jun.2018.
[27]	CLSI, “M100 Performance Standards for Antimicrobial Susceptibility Testing,” 30th ed. Wayne, PA, USA: Clinical and Laboratory Standards Institute; M100-S27. Jan.2020.
[28]	Ejikeugwu, C., Ifeanyichukwu, I., Amaechi, C.O., Ugwu, M., Eze, P., Iroha, C.S., Ogene, L. and Orinya, C, “Multiple Antibiotic Resistance, Antibiogram and Phenotypic Detection of Metallo-Beta Lactamase (MBL) from Escherichia coli of Poultry Origin Abstract,” J Appl Microbiol Biochem, 1(4). 1-5. Aug.2017.
[29]	Ezeador, C. and Agbakoba, N.R, “Prevalence and Identification of BlaVEB-1, Bla and BlaCTX-M in Pseudomonas aeruginosa Isolates from Hospitals in Onitsha Metropolis Using Polymerase Chain Reaction Technique,” Glob J Mol Sci, 11(1). 1-6. Jan.2016.
[30]	Ejikeugwu, C., Esimone, C., Iroha, I., Ugwu, C., Ezeador, C., Duru, C., Duru, C. and Adikwu, M, “Phenotypic Detection of AmpC Beta-Lactamase among Anal Pseudomonas aeruginosa Isolates in a Nigerian Abattoir,” Arch Clin Microbiol, 7(2). 1-5. Jan. 2016.
[31]	Ejikeugwu, C., Esimone, C., Iroha, I., Igwe, D.O., Ugwu, M., Ezeador, C., Duru, C. and Adikwu, M, “Molecular Identification of MBL Genes bla IMP-1 and bla VIM-1 in Escherichia coli Strains Isolated from Abattoir by Multiplex PCR Technique,” Res J Microbiol, 7(12). 266-273. Sep. 2017.
[32]	Akujobi, C.N. and Ezeanya, C.C. “Emergence of Carbapenem Resistance Among Extended Spectrum Beta-Lactamase Isolate Escherichia coli From Clinical Specimens In A Tertiary Hospital, Nigeria,” Int J Microbiol Res, 5(2). 367-370. Mar.2013.
[33]	Easwaran, S., Yerat, R.C. and Ramaswamy, R, “A study on detection of extended-spectrum beta-lactamases (ESBLs) and comparison of various phenotypic methods of AmpC detection in Pseudomonas aeruginosa from various clinical isolates in a tertiary care teaching hospital,” Muller J Med Sci Res. 7(1). 35-39. Jan.2016.
[34]	Ejikeugwu, C., Hasson, S.O., Al-Mosawi, R.M., Alkhudhairy, M.K., Saki, M., Ezeador, C., Ezeh, P., Ugwu, M., Duru, C., Ujam, N.T., Edeh, C., Udu-Ibiam, O., Iroha, I. and Adikwu, M, “Occurrence of FOX AmpC gene among Pseudomonas aeruginosa isolates in abattoir samples from South-Eastern Nigeria,” Rev Med Microbiol, 31(2). 99-103. Apr.2020.
[35]	Cantarelli, V.V., Inamine, E. and Brodt, T.C.Z, Secchi, C., Cavalcante, B.C. and Pereira, F.S, “Utility of the Ceftazidime-Imipenem Antagonism Test (CIAT) to Detect and Confirm the Presence of Inducible AmpC Beta-Lactamases Among Enterobacteriaceae,” The Brazilian J. Infect. Dis, 11(2). 237-239. Apr.2007.
[36]	Ejikeugwu, C., Esimone, C., Iroha, I., Eze, P., Ugwu, M. and Adikwu, M, “Genotypic and Phenotypic Characterization of MBL Genes in Pseudomonas aeruginosa Isolates from the Non-hospital Environment,” J Pure Appl Microbiol, 12(4). 1877-1885. Nov.2018.
[37]	Palewar, M.S., Mudshingkar, S.S., Dohe, V. and Bharadwa, R, “Infection by MultidrugResistant Chryseobacterium indologenes in Cases of Obstructive Uropathy: Case Series with Short Review,” Med J Dr DY Patil Univ. 10. 376-380. Jan.2017.
[38]	Chou, D., Wu, S., Lee, C., Tai, F. and Yu, W, “Clinical Characteristics, Antimicrobial Susceptibilities, and Outcomes of Patients with Chryseobacterium indologenes Bacteremia in an Intensive Care Unit,” Jpn J Infect Dis, 64. 520-524. Sept.2011.
[39]	Bellais, S., Poirel, L., Leotard, S. and Naas, T., Nordmann, P, “Genetic Diversity of Carbapenem-Hydrolyzing Metallo- β-lactamases from Chryseobacterium (Flavobacterium) indologenes,” Antimicrob Agents Chemother, 44(11).3028-3034. Nov.2000.
[40]	Filho, É.B.C., Marson, F.A.L. and Levy, C.E, “Challenges in the identi fi cation of Chryseobacterium indologenes and Elizabethkingia meningoseptica in cases of nosocomial infections and patients with cystic fibrosis,” New Microbes New Infect, 20. 27-33. Sept.2017.
[41]	Alfouzan W, Dhar R, Al-hashemi H, Al-sweih N, Albert MJ. Clinical and microbiological characteristics of Chryseobacterium spp. isolated from neonates in Kuwait. J Med Case Rep. 2014; 2: 1-6.
[42]	Tamai, I.A., Pakbin, B., Kafi, Z.Z. and Brück, W.M, “Oral Abscess Caused by Chryseobacterium indologenes in Ball Python (Python regius): A Case Report,” Antibiotics, 10(686). 1-9. Jun.2021.
[43]	Omar, A., Camara, M., Fall, S., Ngom-cisse, S., Fall, B. and Ba-diallo, A, “Chryseobacterium indologenes in a woman with acute leukemia in Senegal: a case report. J Med Case Rep, 8(1). 1-5. May.2014.
[44]	Matsumoto, T., Nagata, M., Ishimine, N., Kawasaki, K., Yamauchi, K., Hidaka, E., Kasuga, E., Horiuchi, K., Oana, K., Kawakami, Y. and Honda, T, “Characterization of CIA-1, an Ambler Class A Extended-Spectrum β-lactamase from Chryseobacterium indologenes,” Antimicrob Agents Chemother, 56(1). 588-590. Nov.2012.